Table 7Deterministic analysis over a 55-year period

QALYsCost (£)Incremental QALYsIncremental costs (£)ICER (£)
No surveillance16.422320.44
Surveillance – high-risk group only17.1915,785.130.7713,464.6917,557.32

QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio

From: Appendix 7, Cost-effectiveness analysis for inflammatory bowel disease

Cover of Colonoscopic Surveillance for Prevention of Colorectal Cancer in People with Ulcerative Colitis, Crohn's Disease or Adenomas
Colonoscopic Surveillance for Prevention of Colorectal Cancer in People with Ulcerative Colitis, Crohn's Disease or Adenomas.
NICE Clinical Guidelines, No. 118.
Centre for Clinical Practice at NICE (UK).
Copyright © 2011, National Institute for Health and Clinical Excellence.

All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.